secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0000950170-23-063019
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences reports Q3 2023 net loss of $2.6M; cash $14.0M
---------------------------------------------------------------------

- Net loss $2.6M ($0.42/share) vs loss $1.2M ($1.91/share) in Q3 2022; nine-month net income $2.1M on $8.3M warrant gain.
- Cash and equivalents $14.0M at Sep 30, 2023, up from $5.3M at Dec 31, 2022; runway through Sep 2024.
- Operating cash burn for nine months 2023 was $5.3M vs $10.3M in 2022, driven by lower clinical study expenses.
- Gemini preclinical data showed significant mobilization of neutrophils, monocytes, lymphocytes and upregulation of IL-10, NGAL, IL-6.
- Phase 1 clinical study of Gemini expected to begin near end of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017023063019/0000950170-23-063019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017023063019/revb-20231113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-063019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer